CG Oncology

CGON

Market cap $3.42B

42.44 USD

+1.73

4.25%

At close Updated Nov 21, 4:00 PM EST

Pre-market

After hours

42.44

0.00

1 day

4.25%

5 days

2.44%

1 month

-1.44%

3 months

63.36%

6 months

61.86%

Year to date

46.5%

1 year

31.23%

5 years

14.18%

10 years

14.18%

About: CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.

Employees: 113

Healthcare Biotechnology